Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis
Crossref DOI link: https://doi.org/10.1186/s13075-017-1366-1
Published Online: 2017-07-05
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Jin, Yinzhu
Desai, Rishi J.
Liu, Jun
Choi, Nam-Kyong
Kim, Seoyoung C.
Funding for this research was provided by:
Pfizer